Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLICER: Endostar with Second-line Chemotherapy in Recurrent/Metastatic Head and Neck Cancer
NCT03989830Phase 2Unknown
- Start
- Jul 2019
- Primary completion
- Jun 2021
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of endostar in head and neck cancer (HNC). Primary endpoint: Disease Control Rate at 36 months. Status: unknown.
02
Drugs
endostar
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT03989830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03989830.